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ABSTRACT 
ATP-competitive inhibitors of DNA gyrase and topoisomerase IV (topo IV) are among the most 
interesting classes of antibacterial drugs that do not have any representative in the antibacterial 
pipeline. We have developed thirty-two new N-phenylpyrrolamides and evaluated them against 
DNA gyrase and topoisomerase IV from Escherichia coli and Staphylococcus aureus. Antibacterial 
activities were studied against Gram-positive and Gram-negative bacterial strains. The most potent 
compound displayed an IC50 of 47 nM against E. coli DNA gyrase, and a minimum inhibitory 
concentration (MIC) of 12.5 µM against Gram-positive Enterococcus faecalis. Some compounds 
displayed good antibacterial activities against the efflux pump deficient E. coli strain (MICs = 6.25 
µM) and against wild type E. coli in the presence of efflux pump inhibitor PAβN (MIC = 3.13 
µM). We describe here new findings regarding structure-activity relationship of N-
phenylpyrrolamide DNA gyrase B inhibitors and explore factors that are important for antibacterial 
activity of this class of compounds. 
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INTRODUCTION 
Infections are among the major causes of human morbidity and mortality and the pharmaceutical 
industry is not able to keep up with the growing needs for effective novel antibacterials. The main 
reason for this situation is the rapid adaptation of bacteria to antibiotics, which results in the 
development of resistance soon after antibacterial drugs are introduced to therapy.[1] Another 
problem is the low number of new approved antibacterial drugs in the last decades, which is 
associated with the strict regulatory requirements and relatively low cost-to-benefit ratio for 
antibacterial R&D compared to other pharmacological fields.[2][3] 
Bacterial topoisomerases are enzymes that catalyse changes in DNA topology during DNA 
replication, transcription and recombination. They are essential in all bacteria but absent in higher 
eukaryotes, which makes them attractive targets for antibacterial drug discovery. DNA gyrase is 
involved primarily in the negative supercoiling of DNA, while topoisomerase IV is responsible 
mainly for the decatenation of the two daughter chromosomes after replication. DNA gyrase and 
topoisomerase IV both belong to type IIA topoisomerases. They are heterotetrameric enzymes 
composed of two pairs of subunits: two GyrA and two GyrB subunits in DNA gyrase, and two 
ParC and two ParE subunits in topoisomerase IV. The GyrA and GyrB subunits of DNA gyrase 
are similar in amino acid sequence to the ParC and ParE subunits of topoisomerase IV, respectively. 
The main function of GyrA/ParC is cleavage and reunion of DNA, whereas GyrB/ParE binds ATP, 
which is crucial for providing the energy for the conformational movements of the enzyme, 
required for the ligation process.[4] 
There are two main mechanisms of action of drugs targeting DNA gyrase and topoisomerase IV. 
The first is stabilisation of the covalent enzyme–DNA complex, which is typical for the 
fluoroquinolone class of antibacterials.[5] The presence of some serious side effects together with 
the growing bacterial resistance to fluoroquinolones has stimulated the search for inhibitors 
targeting various binding sites on DNA gyrase.[6] The second possible mechanism of action of drugs 
targeting DNA gyrase and topoisomerase IV involves inhibition of ATP binding on the GyrB/ParE 
subunit. Novobiocin, a natural aminocoumarin antibiotic that was withdrawn from the clinic 
because of toxicity, is a classic example of ATP-competitive GyrB inhibitors. In recent decades, 
several new scaffolds have been identified as GyrB and/or ParE inhibitors, such as pyridylureas,[7] 
pyrimidinoindoles,[8] pyrrolopyrimidines,[9] benzimidazole ureas,[10] pyrrolamides,[11] and 
pyrazolopyridones[12] (Figure 1). Even though some of the new inhibitors have advanced to Phase 
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I, none of them has so far reached clinical practice.[13] In the present study, we describe a new series 
of DNA gyrase (GyrB) and topoisomerase IV (ParE) inhibitors, resulting in optimised on-target 
and antibacterial activities. 
 
Figure 1. Representative inhibitors of DNA gyrase (GyrB) and topoisomerase IV (ParE), and their IC50, Ki and MIC 
(S. aureus) values. 
 
RESULTS AND DISCUSSION 
Design. The design of the present series of compounds was based on the crystal structure of N-
phenylpyrrolamide inhibitor A in complex with E. coli DNA gyrase B (Figure 2, PDB code: 
4ZVI),[14] and was aimed at improving its GyrB/ParE inhibitory potency and antibacterial activity. 
Three structural types of compounds (type I-III, Figure 2) were prepared, in which we introduced 
modifications proposed by the detailed study of the binding mode of inhibitor A in the GyrB active 
site, and by molecular docking (Figure 3). In all structural types (I-III) we have retained the 
adjacent hydrogen bond donor (pyrrole NH) and hydrogen bond acceptor (pyrrolamide C=O) 
groups that are necessary for establishing the H-bonding network with Asp73 (E. coli numbering) 
and the structurally conserved water molecule (Figure 2). The amide NH of the pyrrolamide moiety 
was left unsubstituted because it is important for indirect contacts with Asn46 through a crystal 
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water molecule. In some derivatives, we have replaced the 4,5-dibromo-1H-pyrrole group on the 
left-hand side of the molecules with 3,4-dichloro-5-methyl-1H-pyrrole. Thus far, replacing the 4,5-
dibromo-1H-pyrrole moiety by 4-bromo-1H-pyrrole, 1H-indole, or by 4,5-dichloro-1H-pyrrole 
resulted in weaker activity.[14-15] The 3,4-dichloro-5-methyl-1H-pyrrole was selected because the 
chlorine atoms are slightly smaller than the bromine atoms and are thus proposed to bind more 
strongly, not only to DNA gyrase, but also to the slightly smaller binding pockets of S. aureus 
DNA gyrase and topoisomerase IV.[4b,16] Additionally, the 3,4-dichloro-5-methylpyrrole moiety is 
found e.g. in kibdelomycin, a complex antibiotic isolated from extracts of the soil bacterium 
Kibdelosporangium sp.,[17] and in some pyrrolamide DNA gyrase B inhibitors developed by 
AstraZeneca.[11d] 
The right-hand side of the molecules was designed to contain groups able to form ionic 
interactions with Arg136 (e.g. carboxylic acid groups) or π-stacking interactions with the Glu50-
Arg76 salt bridge (e.g. 4-amino-2-hydroxybenzoic acid or 1,3,4-oxadiazol-2-one ring). Whereas 
type I compounds were all glycine derivatives, in some type II compounds, the carboxamide N-
substituent was varied from carboxymethyl (n = 1, Figure 2) to the 2-carboxyethyl group (n = 2, 
Figure 2). In order to improve transport across the bacterial cell membranes, the ionizable terminal 
carboxylic acid functionality was replaced in some type I and type II compounds by its less acidic 
bioisostere 1,3,4-oxadiazol-2-one. The 1,3,4-oxadiazol-2-one ring was proposed to form similar 
interactions with Arg136 as does the terminal carboxylic group, but its lower acidity promises 
better permeability across bacterial membranes and, consequently, better antibacterial activity.[7] 
Additionally, some type I and type II compounds with terminal hydrazide groups were analyzed. 
With the type II series, we have introduced additional alkoxy substituents to the 3-position of the 
central benzene ring. The preliminary docking studies have indicated the possibility of additional 
hydrophobic contacts between these groups and the lipophilic floor of the enzyme formed by the 
amino acid residues Ile94, Ile78, Val120 and Val167 (Figure 3). The size of substituents was 
increased from methoxy, through isopropoxy, to the benzyloxy group. 
Based on the relatively high activity of one of our previously reported inhibitors with only a short 
COCH3 substituent on the para position of the central aminobenzene ring (i.e. N-(4-acetylphenyl)-
4,5-dibromo-1H-pyrrole-2-carboxamide, IC50 = 1.6 µM),[15b] we decided to further explore the 
chemical space around this molecule by preparing a small library of its analogues (type III 
compounds, Figure 2). Analogues were prepared with carboxylic groups attached directly to the 
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central phenyl ring (X = OH, Y = H, Figure 2), compounds with an additional hydroxyl group on 
the phenyl ring (X = OH, Y = OH, Figure 2), and compounds with an acetophenone functionality 
(X = CH3, Y = H, Figure 2). To determine the influence of increased length of the molecules on 
gyrase B and topoisomerase IV inhibition, we prepared a compound with an additional aromatic 
ring (X = 4-NH2-2-OH-(C6H3)-COOH, Y = H, Figure 2). The structure-activity relationships (SAR) 
of all the prepared compounds were studied, enabling the essential structural elements for 
GyrB/ParE inhibition and for antibacterial activity to be determined. 
 
 
Figure 2. Design of three structural types (I-III) of N-phenylpyrrolamides as DNA gyrase B inhibitors, based on the 
co-crystal structure of the inhibitor A – GyrB (E. coli) (PDB code: 4ZVI[14]). 
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Figure 3. The docking binding mode of inhibitors 19f (in magenta) in the ATP binding site of E. coli DNA gyrase B 
(in grey, PDB code: 4DUH[18]). The ligand and the neighbouring protein side-chains are shown as stick models, 
coloured according to the chemical atom type (blue, N; red, O; orange, S; green, Cl). Hydrogen bonds are indicated by 
black dotted lines. 
 
Chemistry. The synthesis of type I compounds (7-11) is presented in Scheme 1. First, 4-
nitrobenzoyl chloride (1) was reacted with glycine methyl ester hydrochloride (2) in the presence 
of potassium carbonate to give compound 3. The nitro group of 3 was reduced by catalytic 
hydrogenation and the obtained amine 4 was coupled with 4,5-dibromopyrrole-2-carboxylic acid 
using N,N,N',N'-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate (TBTU), to yield 
pyrrolamide 5, or with 3,4-dichloro-5-methylpyrrole-2-carboxylic acid chloride prepared in situ 
from the carboxylic acid using oxalyl chloride, to give pyrrolamide 6. Compound 7 was prepared 
by alkaline hydrolysis of methyl ester 6 while hydrazides 8 and 9 were prepared by heating 5 or 6 
with hydrazine at 78 °C. To obtain the target 1,3,4-oxadiazol-2-ones 10 and 11, compounds 8 and 
9 were reacted with 1,1'-carbonyldiimidazole (CDI). 
 
 
Scheme 1. Reagents and conditions: a) K2CO3, CH3CN, 0 °C à rt, 15 h; b) H2, Pd-C, THF, 3 h; c) 4,5-dibromopyrrole-
2-carboxylic acid, TBTU, NMM, CH2Cl2, 50 °C, 15 h (for the synthesis of 5), i)  3,4-dichloro-5-methylpyrrole-2-
carboxylic acid, oxalyl chloride, CH2Cl2, rt, 15 h, then ii) 4, pyridine, CH2Cl2, rt, 15 h (for the synthesis of 6); d) 1 M 
NaOH, THF, rt, 15 h; e) hydrazine monohydrate, EtOH, reflux, 15 h; f) CDI, 1,4-dioxane, 101 °C, 15 h (for the 
synthesis of 10), CDI, DMF, 50 °C, 15 h (for the synthesis of 11). 
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Type II compounds (19a-g, 20 and 21) were synthesized according to Scheme 2. First, methyl 
ester 13 was prepared from 3-hydroxy-4-nitrobenzoic acid (12) and thionyl chloride in methanol. 
The phenolic group of 13 was then alkylated with methyl (compound 14a), isopropyl (compound 
14b) or benzyl (compound 14c) substituents. Compounds 14a and 14c were prepared using methyl 
iodide or benzyl bromide and potassium carbonate as base, while compound 14b was prepared 
using isopropanol under Mitsunobu conditions. Methyl esters 14a-c were hydrolyzed with 1 M 
sodium hydroxide to give carboxylic acids 15a-c, which were subsequently coupled with glycine 
methyl ester hydrochloride to give compounds 16a-c, or with methyl 3-aminopropanoate to give 
compounds 16d-f. The nitro groups of 16a-f were reduced to amino groups by catalytic 
hydrogenation (for products 17a-b, 17d-e) or with tin(II) chloride (for products 17c and 17f). 
Pyrrolamides 18a-c were prepared by coupling 17a-b or 17d with 4,5-dibromopyrrole-2-
carboxylic acid using TBTU methodology, while pyrrolamides 18d-h were prepared from 17a-c 
or 17e-f and the corresponding pyrrole-2-carboxylic acid chloride prepared in situ using oxalyl 
chloride as reagent. Alkaline hydrolysis of compounds 18a-g gave the final products 19a-g, while 
hydrolysis of 18h was unsuccessful. Compound 18b was additionally reacted with hydrazine 
monohydrate to give hydrazide 20, and, after heating 20 with CDI, the final product 21 was 
obtained. 
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Scheme 2. Reagents and conditions: a) thionyl chloride, MeOH, 0 °C à rt, 15 h; b) MeI, K2CO3, DMF, rt, 15 h (for 
the synthesis of 14a), isopropanol, triphenylphosphine, DIAD, THF, rt, 15 h (for the synthesis of 14b), K2CO3, benzyl 
bromide, CH3CN, rt à 60 °C, 3 h (for the synthesis of 14c); c) 1 M NaOH, MeOH, rt, 15 h; d) glycine methyl ester 
hydrochloride (for the synthesis of 16a-c) or methyl 3-aminopropanoate (for the synthesis of 16d-f), TBTU, NMM, 
CH2Cl2, rt, 2-15 h; e) H2, Pd-C, MeOH, rt, 1-4 h (for the synthesis of 17a-b and 17d-e), SnCl2, EtOAc, EtOH, 55 °C, 
24 h (for the synthesis of 17c and 17f); f) i) 4,5-dibromopyrrole-2-carboxylic acid, TBTU, NMM, CH2Cl2, rt, 30 min, 
then ii) 17a or 17b or 17d, DMAP, 60 °C, 15 h (for the synthesis of 18a-c), i) 4,5-dibromopyrrole-2-carboxylic acid, 
oxalyl chloride, CH2Cl2, rt, 15 h, then ii) 17c or 17e or 17f, pyridine, CH2Cl2, rt, 15 h (for the synthesis of 18d and 
18g-h), i) 3,4-dichloro-5-methylpyrrole-2-carboxylic acid, oxalyl chloride, CH2Cl2, rt, 15 h, then ii) 17a or 17b, 
pyridine, CH2Cl2, rt, 15 h (for the synthesis of 18e-f); g) 1-2 M NaOH, MeOH/THF, rt, 15 h; h) hydrazine monohydrate, 
EtOH, reflux, 2 d; i) CDI, 1,4-dioxane, 101 °C, 15 h. 
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Compounds 25a-c and 29 were prepared according to Scheme 3. In the first step, the carboxylic 
acids 22a and 22b were converted to methyl esters using thionyl chloride and methanol. The 
obtained esters 23a and 23b were then coupled with 4,5-dibromopyrrole-2-carboxylic acid or with 
3,4-dichloro-5-methylpyrrole-2-carboxylic acid, as described above, to give compounds 24a-d. 
The final products 25a-c were obtained after alkaline hydrolysis of methyl esters 24a-c. For the 
synthesis of compound 29, first, 4-nitrobenzoyl chloride (1) was reacted with methyl 4-
aminosalicylate (23b) in the presence of pyridine to give the amide 26. After reduction of the nitro 
group of compound 26 by catalytic hydrogenation, the obtained amine 27 was coupled with 4,5-
dibromopyrrole-2-carboxylic acid to give compound 28 which was submitted to alkaline hydrolysis 
to give the final compound 29. 
 
 
Scheme 3. Reagents and conditions: a) thionyl chloride, MeOH, 0 °C à 70 °C, 15 h; b) i) 4,5-dibromopyrrole-2-
carboxylic acid (for the synthesis of 24a-b and 28) or 3,4-dichloro-5-methylpyrrole-2-carboxylic acid (for the synthesis 
of 24c-d), oxalyl chloride, CH2Cl2, rt, 15 h, then ii) 23a or 23b or 23c or 27, pyridine, CH2Cl2, rt, 15 h; c) 1 M NaOH, 
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MeOH/THF, rt à 60 °C, 30 h (for the synthesis of 25a-b and 29), 1 M NaOH, THF, 45 °C, 15 h (for the synthesis of 
25c); d) 1, CH2Cl2, pyridine, rt 15 h; e) H2, Pd-C, MeOH/THF, rt, 3 h. 
 
Inhibitory Activities against DNA Gyrase and Topoisomerase IV. Thirty-two new 
compounds were prepared and evaluated against E. coli DNA gyrase in a supercoiling inhibition 
assay. The results are presented in Tables 1-3 as residual activities (RA) of the enzyme in the 
presence of 10 µM of compounds or as concentrations of compounds that inhibit the enzyme 
activity by 50% (IC50 values). The most active compounds were additionally tested against 
topoisomerase IV from E. coli, and against DNA gyrase and topoisomerase IV from S. aureus. 
In total, twelve compounds displayed IC50 values lower than 0.5 µM against E. coli DNA gyrase, 
three of which (11, 19f and 19g) showed inhibitory activities in the low nanomolar range (IC50 < 
0.1 µM) and their enzymatic inhibition was thus better than that of novobiocin (IC50 = 0.17 µM). 
Generally, compounds containing 3,4-dichloro-5-methylpyrrole groups on the left-hand side of the 
molecules displayed higher activities against E. coli DNA gyrase than compounds containing 4,5-
dibromopyrrole moieties. For example, in the type I series, 3,4-dichloro-5-methylpyrrolamide 11 
(IC50 = 0.080 µM) displayed a four-fold higher activity than its 4,5-dibromopyrrolamide analog 10 
(IC50 = 0.30 µM). Similarly, compound 9 (IC50 = 0.43 µM) was five-times more active than its 4,5-
dibromopyrrolamide analog 8 (IC50 = 2.4 µM). Similar differences in activity could be observed 
between 4,5-dibromopyrrolamides and 3,4-dichloro-5-methylpyrrolamides of the type II (Table 2) 
and type III (Table 3) series. These results indicate that both pyrroles can occupy the hydrophobic 
binding pocket of the enzyme and form hydrophobic interactions with Val71, Val167, Val43 and 
Ala47, but the smaller methyl and chlorine atoms fit better into the enzyme’s binding site. A further 
observation from Tables 1-3 is that compounds containing methyl ester groups on the right-hand 
side show weaker activities than their carboxylic acid counterparts, probably because they cannot 
form ionic interactions with Arg136. This can be seen by comparing the esters 6 (IC50 = 0.41 µM), 
18a (IC50 = 3.7 µM) and 24c (IC50 = 1.6 µM) on the one hand, with the corresponding carboxylic 
acids 7 (IC50 = 0.28 µM), 19a (IC50 = 0.31 µM) and with 25c (IC50 = 0.79 µM) on the other. When 
comparing the activities of compounds with carboxylic acid groups with their hydrazide analogs, 
the former were generally more active. For example, carboxylic acid 7 (IC50 = 0.28 µM) displayed 
greater activity than its hydrazide analogue 9 (IC50 = 0.43 µM), compound A (IC50 = 0.45 µM, 
reported previously)[15b] was more active than the corresponding hydrazide 8 (IC50 = 2.4 µM), and 
  11 
the carboxylic acid 19b (IC50 = 0.16 µM) was more potent than the hydrazide 20 (IC50 = 1.6 µM). 
These differences are, most probably, due to the loss of ionic interactions with Arg136 in the case 
of hydrazide groups. 
There were no significant differences in activity between compounds that contain a 
carboxymethyl (n = 1, Table 2) and those containing the longer 2-carboxyethyl group (n = 2, Table 
2) on the right-hand side of the molecules. Although, in the carboxylic acid subset (compounds 
19a-g, Table 2), the carboxymethyl derivative 19b (IC50 = 0.16 µM) was slightly more active than 
the 2-carboxyethyl derivative 19d (IC50 = 0.36 µM), 19a (IC50 = 0.31 µM) and 19c (IC50 = 0.35 
µM) showed almost no difference in activities. Also, by observing the methyl ester subset 
compounds (18a-h, Table 2) the optimal length of the molecules could not be determined with 
certainty. These results can be due to the high flexibility of this side chain in solution, as recently 
proposed by molecular dynamics simulation.[14] Probably both, the carboxymethyl and the 2-
carboxyethyl groups can adopt conformations in which the terminal carboxylate group is either in 
contact with Arg136 or with the solvent. 
With the introduction of methoxy (compounds 18a, 18e, 19a and 19e, Table 2), isopropoxy 
(compounds 18b, 18d, 18f, 19b, 19d, 19f, 20 and 21, Table 2) or benzyloxy substituents 
(compounds 18g, 18h and 19g, Table 2) at the 3-position of the central benzene ring, we intended 
to make additional contacts with the lipophilic floor of the enzyme. Among the 3,4-dichloro-5-
methylpyrrolamides, the most active was the isopropoxy compound 19f (IC50 = 0.047 µM), 
followed by the methoxy compound 19e (IC50 = 0.12 µM) and the unsubstituted compound 7 (IC50 
= 0.28 µM). In the 4,5-dibromopyrrolamide series the relationship was similar, as the isopropoxy 
compound 19b (IC50 = 0.16 µM) and the methoxy compound 19a (IC50 = 0.31 µM) were both more 
potent than the unsubstituted analog A (IC50 = 0.45 µM). Even though the benzyloxy-substituted 
compound 18g (RA = 21%) did not display significant activity, its carboxylic acid derivative 19g 
(IC50 = 0.087 µM) was among the most potent of the series. Overall, the results indicate that 
lipophilic substituents at the 3-position of the benzene ring are favorable for enhancing interactions 
with the enzyme. 
With the type III series of compounds, we studied the influence of the NH(CH2)nCOOR group 
on the para position of the central aminobenzene ring (compounds 24a-d and 25a-c, Table 3). 
Some prepared compounds lacking the NH(CH2)nCO linker showed good inhibitory activities, e.g. 
compound 24c had an IC50 value of 1.6 µM and its carboxylic acid analogue 25c an IC50 of 0.79 
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µM against E. coli DNA gyrase. These results are particularly interesting when taking into account 
the simple, fragment-like structures of these molecules that could still be optimized. Furthermore, 
two longer molecules, 28 and 29 (Table 3) have been prepared with an additional benzene ring, but 
their activities were weaker, probably because the terminal carboxylic acid group in these 
molecules is too far from Arg136 to form interactions. 
Overall, the activities against S. aureus DNA gyrase, E. coli topoisomerase IV, and S. aureus 
topoisomerase IV were lower than those against E. coli DNA gyrase (Tables 1-3). The two 
compounds with the greatest activity against S. aureus DNA gyrase were 19f with an IC50 of 2.3 
µM and 19e with an IC50 of 4.1 µM. Six other compounds (7, 11, 19a, 19b, 19d and 19g) displayed 
S. aureus DNA gyrase inhibitory activities in the low micromolar range, but none of the compounds 
have reached a comparable inhibition to that of novobiocin with an IC50 value of 41 nM. Seven of 
these compounds contained a free carboxylic acid group, which thus appears crucial for the activity. 
A possible reason for the weaker activities of compounds against S. aureus gyrase is that the 
adenine-binding pocket of this enzyme is slightly smaller than that of E. coli gyrase, which would 
indicate that smaller groups are more effective in binding to the hydrophobic binding site, as 
discussed recently.[15b] In line with this, the two most active compounds against S. aureus gyrase, 
19e (IC50 = 4.1 µM) and 19f (IC50 = 2.3 µM), contain smaller 3,4-dichloro-5-methylpyrrole 
moieties, while the activities of their 4,5-dibromopyrrolamide analogs 19a (IC50 =17 µM) and 19b 
(IC50 = 22 µM) were slightly lower. The most active compound against topoisomerase IV enzyme 
was again compound 19f with an IC50 values of 1.8 µM against E. coli topo IV and 2.7 µM against 
S. aureus topo IV. The weaker activities on E. coli topoisomerase IV than on E. coli DNA gyrase 
are probably due to the previously discussed differences in the binding sites of these enzymes.[15b] 
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Table 1. Inhibitory activities of type I compounds 6-11 against DNA gyrase and topoisomerase IV. 
 
   IC50 (µM)[a] or RA (%)[b] 
Compd R1 R2 E. coli gyrase 
S. aureus 
gyrase 
E. coli 
 topo IV 
S. aureus 
topo IV 
6 3,4-diCl-5-Me COOMe 0.41±0.20 µM n.d.
[c] n.d. n.d. 
7 3,4-diCl-5-Me COOH 0.28±0.21 µM 11±0 µM 100% 100% 
8 4,5-diBr CONHNH2 2.4±1.5 µM 93% 79% 95% 
9 3,4-diCl-5-Me CONHNH2 0.43±0.26 µM 60% 100% 100% 
10 4,5-diBr 
 
0.30±0.09 
µM 100% 98% 100% 
11 3,4-diCl-5-Me 
 
0.080±0.027 
µM 23±5 µM 100% 62% 
novobiocin   0.17 µM 0.041 µM 11 µM 27 µM 
[a] Concentration of compound that inhibits the enzyme activity by 50%. [b] Residual activity of the 
enzyme at 10 µM of the compound. [c] Not determined. 
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Table 2. Inhibitory activities of type II compounds 18a-h, 19a-g, 20 and 21 against DNA gyrase and topoisomerase 
IV. 
 
     IC50 (µM)[a] or RA (%)[b] 
Compd R1 R2 R3 n E. coli gyrase 
S. aureus 
gyrase 
E. coli  
topo IV 
S. aureus 
topo IV 
18a 4,5-diBr Me COOMe 1 3.7±2.1 µM n.d.[c] n.d. n.d. 
18b 4,5-diBr iPr COOMe 1 97% n.d. n.d. n.d. 
18c 4,5-diBr Me COOMe 2 4.2±0.3 µM n.d. n.d. n.d. 
18d 4,5-diBr iPr COOMe 2 3.9±0.8 µM n.d. n.d. n.d. 
18e 3,4-diCl-5-Me Me COOMe 1 0.54±0.36 µM 99% 100% 100% 
18f 3,4-diCl-5-Me iPr COOMe 1 2.3±0.1 µM n.d. n.d. n.d. 
18g 4,5-diBr Bzl COOMe 2 21% n.d. n.d. n.d. 
18h 4,5-diBr Bzl COOMe 1 77% n.d. n.d. n.d. 
19a 4,5-diBr Me COOH 1 0.31±0.11 µM 17±2 µM 85% 96% 
19b 4,5-diBr iPr COOH 1 0.16±0.06 µM 22±4 µM 5.0±5.2 µM 13±10 µM 
19c 4,5-diBr Me COOH 2 0.35±0.10 µM 67% 100% 98% 
19d 4,5-diBr iPr COOH 2 0.36±0.29 µM 28±10 µM 76% 90% 
19e 3,4-diCl-5-Me Me COOH 1 0.12±0.10 µM 
4.1±2.9 
µM 99% 65% 
19f 3,4-diCl-5-Me iPr COOH 1 0.047±0.021 µM 
2.3±0.5 
µM 1.4±0.5 µM 2.3±0.7 µM 
19g 4,5-diBr Bzl COOH 2 0.087±0.052 µM 20±5 µM 100% 98% 
20 4,5-diBr iPr CONHNH2 1 1.6±0.0 µM n.d. n.d. n.d. 
21 4,5-diBr iPr 
 
1 1.7±0.0 µM 65% 100% 99% 
novobiocin     0.17 µM 0.041 µM 11 µM 27 µM 
[a] Concentration of compound that inhibits the enzyme activity by 50%. [b] Residual activity of the enzyme at 10 
µM of the compound. [c] Not determined. 
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Table 3. Inhibitory activities of type III compounds 24a-d, 25a-c, 28 and 29 against DNA gyrase and 
topoisomerase IV. 
 
    IC50 (µM)[a] or RA (%)[b] 
Compd R1 R2 R3 E. coli gyrase 
S. aureus 
gyrase 
E. coli 
topo IV 
S. aureus 
topo IV 
24a 4,5-diBr H OMe 5.8±1.7 µM n.d.[c] n.d. n.d. 
24b 4,5-diBr OH OMe 94% n.d. n.d. n.d. 
24c 3,4-diCl-5-Me H OMe 1.6±0.5 µM 100% 94% 100% 
24d 3,4-diCl-5-Me H Me 0.72±0.09 µM 100% 100% 100% 
25a 4,5-diBr H OH 2.9±0.4 µM n.d. n.d. n.d. 
25b 4,5-diBr OH OH 2.7±0.1 µM n.d. n.d. n.d. 
25c 3,4-diCl-5-Me H OH 0.79±0.02 µM 62% 11±2 µM 45±4 µM 
28 4,5-diBr H 4-NH-2-OH-(C6H3)-COCH3 80% n.d. n.d. n.d. 
29 4,5-diBr H 4-NH-2-OH-(C6H3)-COOH 
0.60±0.37 
µM n.d. n.d. n.d. 
novobiocin     0.17 µM 0.041 µM 11 µM 27 µM 
[a] Concentration of compound that inhibits the enzyme activity by 50%. [b] Residual activity of the enzyme at 
10 µM of the compound. [c] Not determined. 
 
Antibacterial Activity. Compounds were evaluated against two Gram-positive (S. aureus 
ATCC 25923 and Enterococcus faecalis ATCC 29212) and two Gram-negative (E. coli ATCC 
25922 and Pseudomonas aeruginosa ATCC 27853) wild type bacterial strains at 50 µM 
concentration. Results are presented in Table 1S (Supporting information) as percent inhibition of 
growth after 24 h incubation. In general, the activities against Gram-positive bacteria were greater 
than those against Gram-negative bacteria. This could be due to difficulties in permeation of 
compounds through the Gram-negative bacterial cell wall, or to efflux of inhibitors from the 
bacteria. In total, nine compounds (6, 9, 11, 18f, 19f, 19g, 21, 25c and 29) inhibited the growth of 
Gram-positive E. faecalis by more than 50% at 50 µM concentration, four of which (6, 11, 19f and 
25c) displayed more than 70% inhibition of growth. Compound 11 also showed 64% inhibition of 
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growth of S. aureus and 51% inhibition of growth of Gram-negative E. coli (Table 1S). The results 
of the minimum inhibitory concentration (MIC) experiments against S. aureus, E. faecalis and E. 
coli for the most interesting compounds are presented in Table 4. The MIC values for compounds 
11 and 19f against E. faecalis were 12.5 µM and 50 µM (MIC for ciprofloxacin = 3.02 µM). The 
MIC value for compound 11 against S. aureus was 75 µM (MIC for ciprofloxacin = 1.51 µM). With 
other tested compounds, the MIC level (≥ 90% inhibition) was not reached even at the highest 
concentration of 125 µM (Table 4). The highest antibacterial activity of compound 11 is in line 
with our design strategy, that the bioisosteric replacement of the terminal carboxylic acid group 
with the 1,3,4-oxadiazol-2-one ring might lead to easier entry of inhibitors into the bacterial cell 
due to their lower acidity and polarity. 
 
Table 4. Minimum inhibitory concentrations (MICs) of compounds 6, 11, 19f, 19g, 21, 25c and 29 against 
S. aureus (ATCC 25923), E. faecalis (ATCC 29212) and E. coli (ATCC 25922). 
Compd 
MIC (µM)[a] 
S. aureus (ATCC 25923) E. faecalis (ATCC 29212) E. coli (ATCC 25922) 
6 n.d.[b] >125 n.d. 
11 75 12.5 >125 
19f n.d. 50 n.d. 
19g >125 >125 n.d. 
21 >125 >125 n.d. 
25c n.d. >125 n.d. 
29 n.d. >125 n.d. 
[a]  MIC = minimum inhibitory concentration (µM) that inhibited the growth of bacteria by ≥ 90%. MIC 
values of the positive control ciprofloxacin against S. aureus, E. faecalis and E. coli were 1.51, 3.02 and 
0.05 µM. [b] Not determined. 
 
Fifteen compounds (6, 7, 9, 11, 18f, 19f, 24a-d, 25a, 25b, 25c, 28 and 29) were additionally 
tested against two E. coli mutant strains, JD17464 and JW5503. E. coli JD17464 is an lpxC deletion 
mutant with impaired outer membrane, while E. coli JW5503 is a tolC deletion mutant with a 
defective efflux pump. Inhibition of growth was measured at 50 µM concentration of compounds 
after 24 h incubation (Table 2S). MIC values for six selected compounds (6, 9, 11, 19f, 24a and 
25c) against E. coli JW5503 are presented in Table 5. The activities against the mutant with 
impaired outer membrane (JD17464) were comparable with those against wild type E. coli. On the 
other hand, activities against the mutant with a defective efflux pump (JW5503) were greater for 
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the majority of the tested compounds. The most active compound was oxadiazolone 11 with an 
MIC value of 6.25 µM, followed by a type III compound 25c with 25 µM MIC. Compounds 6, 9, 
19f and 24a had an MIC of 50 µM. These results indicate that the efflux of inhibitors is probably 
the major factor causing the lower activities of these compounds against the Gram-negative 
bacteria. To confirm these findings, compounds 6, 9, 11, 19f and 25c were additionally evaluated 
against wild type E. coli in the presence of 100 µg/mL concentration of efflux inhibitor 
phenylalanine-arginine β-naphthylamide (PAβN)[19] (Table 5). The most active compound was 
again compound 11, with an MIC of 3.13 µM, followed by 25c with an MIC of 12.5 µM, and 
compounds 6 (MIC = 25 µM), 19f (MIC = 25 µM) and 9 (MIC = 50 µM). Observing the inhibitory 
activity of compound 11 against wild type E. coli with and without PAβN at different time-points 
(4, 8 and 24 h) clearly demonstrates that this compound is able to affect the growth in the 
logarithmic growth phase also without PAβN, but that at the 24 h end-point the inhibitory activity 
no longer reaches the MIC (Figure 1S). In the presence of PAβN, stronger inhibition is seen at all 
time points. These results confirm that, in Gram-negative bacteria, the prepared compounds are 
most probably substrates for efflux pumps, which should be taken into account in the design of all 
future series of N-phenylpyrrolamide inhibitors. As has been demonstrated for the 
pyrrolopyrimidine series of DNA gyrase inhibitors,[9] despite the susceptibility to efflux, it is 
nevertheless possible to achieve good MICs against Gram-negative bacteria.  
 
Table 5. Minimum inhibitory concentrations (MIC) of compounds 6, 9, 11, 19f 
and 25c against the efflux pump deficient strain E. coli JW5503, and against 
wild type E. coli in the presence of efflux inhibitor PAβN. 
Compd MIC (µM)
[a] 
E. coli (JW5503)[b] E. coli (ATCC 25922) with PaβN[c] 
6 50 25 
9 50 50 
11 6.25 3.13 
19f 50 25 
24a 50 n.d.[d] 
25c 25 12.5 
[a] MIC = minimum inhibitory concentration that inhibited the growth of 
bacteria by ≥ 90%. Ciprofloxacin was used as a positive control. [b] E. coli 
tolC deletion mutant with defective efflux pump. [c] Phenylalanine-arginine β-
naphthylamide; an efflux pump inhibitor. The tests were performed in the 
presence of 100 µg/mL concentration of PAβN. [d] Not determined. 
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CONCLUSION 
Despite the huge amount of research work, there are currently no inhibitors of the ATPase 
activities of DNA gyrase and/or topoisomerase IV in clinical use. To optimise and further develop 
the promising class of N-phenylpyrrolamide DNA gyrase B inhibitors, we have designed and 
prepared thirty-two new compounds of this class and evaluated their activities against DNA gyrase 
and topoisomerase IV from E. coli and S. aureus. The most potent compounds, 11, 19f and 19g, 
had IC50 values against E. coli DNA gyrase in the low nanomolar range (IC50 < 100 nM). The 
activities against DNA gyrase from S. aureus and against topoisomerase IV were lower. The most 
potent compound, 11, had an MIC value of 12.5 µM against Gram-positive E. faecalis. Even though 
the activities against wild type Gram-negative E. coli were lower, interesting results were obtained 
against the efflux pump deficient and against the wild type E. coli strains in the presence of efflux 
pump inhibitor PAβN, where the MICs of compound 11 were 6.25 µM and 3.13 µM, respectively. 
These results indicate that major factor responsible for the lower activity of this type of compounds 
against the Gram-negative bacteria is their efflux from the cells. These results should be taken into 
account in the design of future series of this class of GyrB inhibitors.  
 
EXPERIMENTAL SECTION 
 
Determination of Inhibitory Activities on E. coli and S. aureus DNA Gyrase. Inhibitory 
activities were determined in an assay from Inspiralis on streptavidin-coated 96-well microtiter 
plates from Thermo scientific Pierce. First, the plates were rehydrated with buffer (20 mM Tris-
HCl with pH 7.6, 0.01% w/v BSA, 0.05% v/v Tween 20, 137 mM NaCl) and the biotinylated 
oligonucleotide was then immobilized. After washing off the unbound oligonucleotide, the enzyme 
test was performed. The reaction volume of 30 μL in buffer (35 mM Tris × HCl with pH 7.5, 4 
mM MgCl2, 24 mM KCl, 2 mM DTT, 1.8 mM spermidine, 1 mM ATP, 6.5 % w/v glycerol, 0.1 
mg/mL albumin) contained 1.5 U of DNA gyrase from E. coli or S. aureus, 0.75 μg of relaxed 
pNO1 plasmid, and 3 μL solution of the inhibitor in 10% DMSO and 0.008% Tween 20. Reaction 
solutions were incubated at 37 °C for 30 min. After that, the TF buffer (50 mM NaOAc with pH 
5.0, 50 mM NaCl and 50 mM MgCl2) was added to terminate the enzymatic reaction. After 
additional incubation for 30 min at rt, during which biotin-oligonucleotide-plasmid triplex was 
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formed, the unbound plasmid was washed off using TF buffer and SybrGOLD in T10 buffer (10 
mM Tris HCl with pH 8.0 and 1 mM EDTA) was added. The fluorescence was measured with a 
microplate reader (BioTek Synergy H4, excitation: 485 nm, emission: 535 nm). Initial screening 
was done at 100 or 10 μM concentration of inhibitors. For the most active inhibitors IC50 was 
determined using seven concentrations of tested compounds. GraphPad Prism software was used 
to calculate the IC50 values. The result is given as the average value of three independent 
measurements. As the internal standard novobiocin (IC50 = 0.168 µM (lit.[20] 0.08 µM) for E. coli 
gyrase and IC50 = 0.041 µM (lit.[20] 0.01 µM) for S. aureus gyrase) was used. 
Determination of Inhibitory Activities on E. coli and S. aureus Topoisomerase IV. IC50 
values were determined in an assay from Inspiralis on streptavidin-coated 96-well microtiter plates 
from Thermo scientific Pierce. First, the plates were rehydrated with buffer (20 mM Tris-HCl with 
pH 7.6, 0.01% w/v BSA, 0.05% v/v Tween 20, 137 mM NaCl) and biotinylated oligonucleotide 
was then immobilized. After washing off the unbound oligonucleotide, the enzyme test was 
performed. The reaction volume of 30 μL in buffer (40 mM HEPES KOH with pH 7.6, 100 mM 
potassium glutamate, 10 mM magnesium acetate, 10 mM DTT, 1 mM ATP, 0.05 mg/mL albumin) 
contained 1.5 U of topoisomerase IV from E. coli or S. aureus, 0.75 μg of pNO1 supercoiled 
plasmid, and 3 μL solution of the inhibitor in DMSO (10%) and Tween 20 (0.008%). Reaction 
mixtures were incubated at 37 °C for 30 min and after that, the TF buffer (50 mM NaOAc with pH 
5.0, 50 mM NaCl and 50 mM MgCl2) was added to terminate the enzymatic reaction. After 
additional incubation for 30 min at rt, during which triplex (biotin-oligonucleotide-plasmid) was 
formed, the unbound plasmid was washed off using TF buffer and SybrGOLD in T10 buffer (10 
mM Tris HCl with pH 8.0 and 1 mM EDTA) was added. The fluorescence was measured with a 
microplate reader (BioTek Synergy H4, excitation: 485 nm, emission: 535 nm). Initial screening 
was done at 100 or 10 μM concentration of inhibitors. For the most active inhibitors IC50 was 
determined using seven concentrations of tested compounds. GraphPad Prism software was used 
to calculate the IC50 values. The result is given as the average value of three independent 
measurements. As the internal standard novobiocin (IC50 = 11.1 µM (lit.[20] 10 µM) for E. coli 
topoisomerase IV and IC50 = 26.7 µM (lit.[20] 20 µM) for S. aureus topoisomerase IV) was used. 
Determination of Antibacterial Activity. Clinical microbiology control strains of Enterococcus 
faecalis (ATCC 29212), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 
27853), and Staphylococcus aureus (ATCC 25923) were obtained from Microbiologics Inc. (St. 
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Cloud, Minnesota, USA). Single-gene knock-out mutant strains of E. coli, JW5503 (tolC knock-
out)[21] and JD17464 (lpxC knock-out), were obtained from the NBRP-E.coli collection at the 
National Institute of Genetics (NIG, Japan). To determine antibacterial activity, broth microdilution 
assays in 96-well plates were carried out by following the CLSI guidelines.[22] For selected 
compounds minimum inhibitory concentrations (MIC) were determined by dose-response 
experiments (reported values are from at least two independent experiments, each with three 
replicates per concentration). In the experiments with the efflux inhibitor, the assay media was 
supplemented with 100 µg/mL of Phe-Arg-β-naphthylamide (PAβN; Sigma-Aldrich, Switzerland). 
Molecular Modeling. 
Protein and Ligand Preparation. 3D compound models were built using ChemBio3D Ultra 
16.0.[23] MMFF94 force field[24] was used for the optimization of geometries and partial atomic 
charges were added. Energy was minimized to less than 0.001 kcal/(mol Å) gradient value. The 
structure was refined with GAMESS interface using PM3 method, QA optimization algorithm and 
Gasteiger Hückel charges for all atoms for 100 steps.[23] GOLD Suite v5.4[25][26] was used for 
molecular docking calculations. GOLD graphical user interface was used for receptor preparation. 
To the protein hydrogen atoms were added and correct tautomers and protonation states were 
assigned. Except for HOH614, all water molecules and ligands were deleted from the crystal 
structure. Amino acid residues within 7 Å around the ligand (PDB entry: 4DUH[18]) were selected 
as the binding site. 
Ligand Docking. Compounds were docked to the defined binding site in 25 independent genetic 
algorithm (GA) runs by applying different GA parameters (population size = 100, selection 
pressure = 1.1, number of operations = 100,000, niche size = 2, number of islands = 5, mutation 
frequency = 95, crossover frequency = 95, migration frequency = 10) and scoring functions 
(GoldScore, ChemScore, CHEMPLP). The most representative results were obtained using 
GoldScore as a scoring function. Ligands with RMSD value less than 1.5 Å were joined in clusters 
and early termination was allowed if the top 3 solutions were within 1.0 Å of the RMSD value. 
Proposed binding modes of the top 5 highest scored docking poses were evaluated for each ligand 
and used for graphical representation in PyMOL.[27] 
Chemistry. Chemicals were obtained from Apollo Scientific (Stockport, UK), Sigma-Aldrich 
(St. Louis, MO, USA) and Acros Organics (Geel, Belgium). TLC analyses were performed on 
Merck 60 F254 plates (0.25 mm). Flash column chromatography was performed on silica gel 60 
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(particle size 240–400 mesh). For HPLC analyses an Agilent Technologies 1100 instrument 
(Agilent Technologies, CA, USA) with a G1313A autosampler, a G1316A thermostat and a 
G1365B UV-Vis detector was used. An Agilent Eclipse Plus C18 column was used (5 µm, 4.6 × 
150 mm) with a flow rate of 1.0 mL/min. Melting points were determined on a hot-stage 
microscope from Reichert and are uncorrected. 1H and 13C NMR spectra were recorded at 400 and 
100 MHz on a Bruker AVANCE III 400 spectrometer (Bruker Corporation, MA, USA) as 
[D6]DMSO or CDCl3 solutions. For the IR measurements, a Thermo Nicolet Nexus 470 ESP FT-
IR spectrometer (Thermo Fisher Scientific, MA, USA) was used. Mass spectra were recorded on 
an Advion CMS spectrometer (Advion Inc., Ithaca, USA) or VG Analytical Autospec Q mass 
spectrometer (Fisons, VG Analytical, Manchester, UK). All tested compounds were more than 
95% pure as established by HPLC. 
Synthetic Procedures. 
Methyl (4-nitrobenzoyl)glycinate (3).[15b] To a suspension of glycine methyl ester hydrochloride 
(2) (0.677 g, 5.39 mmol) and potassium carbonate (2.23 g, 16.17 mmol) in acetonitrile (50 mL) 
cooled to 0 °C, a solution of 4-nitrobenzoil chloride (1) (1.00 g, 5.39 mmol) in acetonitrile (10 mL) 
was added dropwise. After 15 h of stirring at rt, the solvent was evaporated under reduced pressure, 
the residue dissolved in ethyl acetate (100 mL) and washed with water (2 × 20 mL) and brine (20 
mL). The organic phase was dried over Na2SO4, filtered and the solvent evaporated under reduced 
pressure to afford 3 (929 mg) as yellow crystals. Yield 72% (0.929 g); 1H NMR (400 MHz, 
[D6]DMSO): δ = 3.68 (s, 3H, CH3), 4.07 (d, 2H, 3J = 5.6 Hz, CH2), 8.11 (d, 2H, 3J = 8.8 Hz, Ar-H-
2,6), 8.36 (d, 2H, 3J = 8.8 Hz, Ar-H-3,5), 9.34 (t, 1H, 3J = 5.6 Hz, CONH). 
General procedure A. Synthesis of Compounds 4, 17a-b, 17d-e and 27 (with 4 as an 
Example). Compound 3 (0.920 g, 3.86 mmol) was dissolved in THF (50 mL), Pd/C (200 mg) was 
added and the reaction mixture was stirred under hydrogen atmosphere for 3 h. The catalyst was 
filtered off and the solvent removed under reduced pressure to obtain 4 (0.796 g) as white crystals. 
Methyl (4-aminobenzoyl)glycinate (4). White crystals; yield 99% (0.796 g); mp: 129-131 °C 
(130-131 °C, lit.[28]); 1H NMR (400 MHz, [D6]DMSO): δ = 3.64 (s, 3H, CH3), 3.93 (d, 2H, 3J = 5.6 
Hz, CH2), 5.68 (s, 2H, NH2), 6.55 (d, 2H, 3J = 8.4 Hz, Ar-H-3,5), 7.58 (d, 2H, 3J = 8.4 Hz, Ar-H-
2,6), 8.46 (s, 1H, CONH); 13C NMR (100 MHz, CDCl3): δ = 41.87 (CH2), 52.74 (CH3), 123.90, 
128.35, 139.15, 149.80, 165.45 (C=O), 170.20 (C=O); IR (ATR): ν = 3440, 3352, 3241, 2955, 
2939, 1751, 1635, 1501, 1439, 1411, 1367, 1300, 1205, 1179, 1001, 983, 838, 768 cm-1. 
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General procedure B. Synthesis of Compounds 6, 18d-h and 24b-d (with 6 as an Example). 
To a suspension of 3,4-dichloro-5-methylpyrrole-2-carboxylic acid (280 mg, 1.44 mmol) in 
anhydrous dichloromethane (16 mL) oxalyl chloride (2 M solution in dichloromethane, 2.20 mL, 
4.32 mmol) was added and the mixture stirred at rt for 15 h. The solvent was removed under 
reduced pressure, fresh anhydrous dichloromethane (4 mL), pyridine (2 mL) and compound 4 (300 
mg, 1.44 mmol) were added and the reaction mixture was stirred at rt for 15 h. The solvent was 
removed under reduced pressure, the residue dissolved in ethyl acetate (20 mL) and washed with 
1 M HCl (2 × 20 mL) and brine (2 × 20 mL). The organic phase was dried over Na2SO4, filtered 
and the solvent removed under reduced pressure. To the residue ether (15 mL) was added, the 
obtained suspension was sonicated, filtered off, washed with ether (2 × 5 mL) and dried to afford 
6 (245 mg) as a brown solid. 
Methyl (4-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)benzoyl)glycinate (6). Brown 
solid; yield 42% (245 mg); mp: >300 °C; 1H NMR (400 MHz, [D6]DMSO): δ = 2.25 (s, 3H, CH3), 
3.67 (s, 3H, COOCH3), 4.01 (d, 2H, 3J = 6.0 Hz, CH2), 7.77 (d, 2H, 3J = 8.8 Hz, Ar-H-2,6), 7.88 
(d, 2H, 3J = 8.8 Hz, Ar-H-3,5), 8.89 (t, 1H, 3J = 6.0 Hz, NHCH2), 9.73 (s, 1H, NHAr), 12.29 (s, 1H, 
Pyrr-NH); 13C NMR (100 MHz, [D6]DMSO): δ = 10.79 (Pyrr-CH3), 41.17 (CH2), 51.71 
(COOCH3), 108.62, 111.90, 119.00, 119.29, 128.14, 128.29, 141.53, 157.30, 166.01, 170.48, signal 
for one C atom not seen; IR (ATR): ν = 3386, 3245, 2953, 1735, 1640, 1593, 1522, 1504, 1312, 
1216, 1182, 848 cm-1; MS (ESI) m/z = 384.1 (MH+); HRMS for C16H16Cl2N3O4: calculated 
384.0518, found 384.0513; HPLC: Agilent Eclipse Plus C18 column (5 µm, 4.6 × 150 mm); mobile 
phase: 30–90% of acetonitrile in TFA (0.1%) in 16 min, 90% acetonitrile to 20 min; flow rate 1.0 
mL/min; injection volume: 10 μL; retention time: 9.654 min (95.1 % at 280 nm). 
General procedure C. Synthesis of Compounds 7, 15a-c, 19e-f and 25c (with 7 as an 
Example). To a stirred solution of compound 6 (48 mg, 0.12 mmol) in THF (15 mL) 1 M NaOH 
(240 µL, 0.24 mmol) was added. The mixture was stirred at rt for 15 h, concentrated under reduced 
pressure and the residue was acidified with 1 M HCl to pH 1. The product was extracted with ethyl 
acetate (2 × 20 mL), the combined organic phases washed with water (2 × 20 mL) and brine (20 
mL), dried over Na2SO4, filtered and the solvent evaporated under reduced pressure. To the residue 
ether (5 mL) was added, the obtained suspension was sonicated, filtered off, washed with ether (2 
× 3 mL) and dried to give 7 (25 mg) as a brown solid. 
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(4-(3,4-Dichloro-5-methyl-1H-pyrrole-2-carboxamido)benzoyl)glycine (7). Brown solid; 
yield 52% (25 mg); mp: >250 °C; 1H NMR (400 MHz, [D6]DMSO): δ = 2.25 (s, 3H, CH3), 3.92 
(d, 2H, 3J = 6.0 Hz, CH2), 7.80 (d, 2H, 3J = 8.8 Hz, Ar-H-3,5/2,6), 7.88 (d, 2H, 3J = 8.8 Hz, Ar-H-
3,5/2,6), 8.78 (t, 1H, 3J = 6.0 Hz, NHCH2), 9.85 (s, 1H, NHAr), 12.44 (s, 1H, Pyrr-NH), 12.59 (s, 
1H, COOH); 13C NMR (100 MHz, [D6]DMSO): δ = 10.77 (CH3), 41.14 (CH2), 108.75, 112.64, 
118.85, 118.96, 128.05, 128.41, 141.64, 157.16, 165.87, 171.42, signal for one C atom not seen; 
IR (ATR): ν = 3355, 3246, 2979, 2935, 1728, 1647, 1595, 1524, 1142, 1317, 1215, 877, 762 cm-1; 
MS (ESI) m/z = 370.0 (MH+); HRMS for C15H14Cl2N3O4: calculated 370.0361, found 370.0351; 
HPLC: Agilent Eclipse Plus C18 column (5 µm, 4.6 × 150 mm); mobile phase: 30–90% of 
acetonitrile in TFA (0.1%) in 16 min, 90% acetonitrile to 20 min; flow rate 1.0 mL/min; injection 
volume: 10 μL; retention time: 7.995 min (98.5 % at 280 nm). 
General procedure D. Synthesis of Compounds 8, 9 and 20 (with 8 as an Example). To the 
solution of compound 5 (96 mg, 0.209 mmol) in absolute ethanol (10 mL) hydrazine monohydrate 
(101 µL, 2.09 mmol) was added and the mixture was stirred at reflux for 15 h. The solvent was 
evaporated under reduced pressure, to the residue absolute ethanol (10 mL) was added, the obtained 
precipitate was filtered off and dried to give 8 (25 mg) as a white solid. 
4,5-Dibromo-N-(4-((2-hydrazineyl-2-oxoethyl)carbamoyl)phenyl)-1H-pyrrole-2-
carboxamide (8). White solid; yield 26% (25 mg); mp: 265-266 °C; 1H NMR (400 MHz, 
[D6]DMSO): δ = 3.83 (d, 2H, 3J = 6.0 Hz, CH2), 4.26 (s, 2H, NH2), 7.28 (s, 1H, Pyrr-CH), 7.80 (d, 
1H, 3J = 8.8 Hz, Ar-H-3,5), 7.88 (d, 1H, 3J = 8.8 Hz, Ar-H-2,6), 8.63 (t, 1H, 3J = 6 Hz, NHCH2), 
9.14 (s, 1H, NHNH2), 10.05 (s, 1H, NHAr), 12.97 (s, 1H, Pyrr-NH); 13C NMR (100 MHz, 
[D6]DMSO): δ = 56.01 (CH2), 98.26, 106.39, 114.17, 118.91, 127.65, 128.17, 128.66, 141.52, 
157.41, 165.92, 168.43; IR (ATR): ν = 3293, 3210, 3108, 1634, 1592, 1513, 1406, 1388, 1329, 
1289, 1247, 185, 1139, 1063, 998, 970, 931, 883, 829, 805, 754, 649 cm-1; MS (ESI) m/z = 455.9 
([M-H]-); HRMS for C14H13Br2N5O3: calculated 455.9307, found 455.9298; HPLC: Agilent Eclipse 
Plus C18 column (5 µm, 4.6 × 150 mm); mobile phase: 30–90% acetonitrile in TFA (0.1%) in 16 
min, 90% acetonitrile to 20 min; flow rate 1.0 mL/min; injection volume: 10 μL; retention time: 
4.777 min (95.8% at 280 nm).  
General procedure E. Synthesis of Compounds 10 and 21 (with 10 as an Example). The 
suspension of compound 8 (108 mg, 0.235 mmol) and 1,1'-carbonyldiimidazole (CDI, 57 mg, 0.353 
mmol) in 1,4-dioxane (15 mL) was stirred at 101 °C for 15 h upon which a clear solution formed. 
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The solvent was removed under reduced pressure and the oily residue was purified with flash 
column chromatography using dichloromethane/methanol (20/1) as an eluent to afford 10 (25 mg) 
as a white solid. 
4,5-Dibromo-N-(4-(((5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)carbamoyl)phenyl)-
1H-pyrrole-2-carboxamide (10). White solid, yield 22% (25 mg); mp: 261-263 °C; 1H NMR (400 
MHz, [D6]DMSO): δ = 4.37 (d, 2H, 3J = 5.2 Hz, CH2), 7.28 (s, 1H, Pyrr-CH), 7.82 (d, 1H, 3J = 8.8 
Hz, Ar-H-2,6/3,5), 7.87 (d, 1H, 3J = 8.8 Hz, Ar-H-2,6/3,5), 8.98 (t, 1H, 3J = 5.6 Hz, NHCH2), 10.07 
(s, 1H, NHAr), 12.25 (s, 1H, NH), 12.97 (s, 1H, NH); 13C NMR (100 MHz, [D6]DMSO): δ = 35.06 
(CH2), 98.27, 106.46, 114.23, 119.03, 127.60, 127.95, 128.18, 141.89, 154.48, 154.85, 157.42, 
165.93; IR (ATR): ν = 2231, 1761, 1639, 1593, 1544, 1519, 1410, 1388, 1322, 1246, 1224, 1186, 
1093, 933, 848, 768, 647cm-1; MS (ESI) m/z = 481.9 ([M-H]-); HRMS for C15H11Br2N5O4: 
calculated 481.9100, found 481.9110; HPLC: Agilent Eclipse Plus C18 column (5 µm, 4.6 × 150 
mm); mobile phase: 30–90% acetonitrile in TFA (0.1%) in 16 min, 90% acetonitrila to 20 min; 
flow rate 1.0 mL/min; injection volume: 10 μL; retention time: 7.578 min (98.0% at 280 nm). 
General procedure F. Synthesis of Compounds 13 and 23a-b (with 13 as an Example). To 
the solution of 3-hydroxy-4-nitrobenzoic acid (12) (10.00 g, 55 mmol) in methanol (500 mL) 
cooled on ice bath thionyl chloride (32.20 mL, 165 mmol) was added dropwise. The mixture was 
stirred at rt for 15 h. The solvent was evaporated under reduced pressure to obtain 13 (10.35 g) as 
a yellow solid. 
Methyl 3-hydroxy-4-nitrobenzoate (13). Yellow solid, yield 97% (10.53 g); mp: 87-91 °C (86-
88 °C, lit.[29]); 1H NMR (400 MHz, [D6]DMSO): δ = 3.88 (s, 3H, COOCH3), 7.49 (dd, 1H,  3J = 8.4 
Hz, 4J = 1.6 Hz, Ar-H-6), 7.69 (d, 1H,  4J = 1.6 Hz, Ar-H-2), 7.96 (d, 1H, 3J = 8.4 Hz, Ar-H-5), 
11.52 (s, 1H, OH); 13C NMR (100 MHz, [D6]DMSO): δ = 52.73 (CH3), 119.33, 119.39, 125.51, 
134.44, 140.15, 151.26, 164.72 (C=O); IR (ATR): ν = 3305, 3053, 2960, 1720, 1622, 1586, 1521, 
1476, 1434, 1323, 1283, 1220, 1147, 1097, 1066,  966, 891, 842, 797, 780, 743, 666 cm-1. 
Methyl 3-methoxy-4-nitrobenzoate (14a).[30] To a stirred suspension of compound 13 (3.43 g, 
17.4 mmol) and potassium carbonate (3.61 g, 26.1 mmol) in N,N-dimethylformamide (30 mL) 
methyl iodide (2.20 mL, 34.8 mmol) was added dropwise. The mixture was stirred at rt for 15 h, 
concentrated under reduced pressure, the residue was dissolved in ethyl acetate (20 mL) and the 
organic phase was washed with water (2 × 30 mL) and brine (30 mL). The organic phase was dried 
over Na2SO4, filtered and the solvent removed under reduced pressure to obtain 14a (3.01 g) as a 
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pale yellow solid. Yield 82% (3.01 g); mp: 90-93 °C; 1H NMR (400 MHz, [D6]DMSO): δ = 3.92 
(s, 3H, OCH3), 4.01 (s, 3H, COOCH3), 7.68 (dd, 1H, 3J = 8.4 Hz, 4J = 1.2 Hz, Ar-H-6), 7.78 (d, 
1H, 4J = 1.2 Hz, Ar-H-2), 8.00 (d, 1H, 3J = 8.4 Hz, Ar-H-5); 13C NMR (100 MHz, [D6]DMSO): δ 
= 52.84 (COOCH3), 56.86 (OCH3), 114.43, 121.22, 125.10, 134.27, 142.13, 151.48, 164.72 
(COOCH3); IR (ATR): ν = 2959, 1726, 1610, 1587, 1523, 1487, 1435, 1408, 1348, 1290, 1241, 
1186, 1147, 1114, 1083, 1019, 983, 914, 887, 837, 788, 772, 742, 685, 616 cm-1; MS (ESI) m/z = 
212.1 (MH+); HRMS for C9H10NO5: calculated 212.0559, found 212.0554. 
3-Methoxy-4-nitrobenzoic acid (15a). Synthesized according to General procedure C with 
methanol (50 mL) as solvent. Pale yellow solid; yield 86 % (2.38 g); mp: 229-233 °C (230-233 °C, 
lit.[31]); 1H NMR (400 MHz, [D6]DMSO): δ = 3.99 (s, 3H, OCH3), 7.66 (dd, 1H, 3J = 8.4 Hz, 4J = 
1.2 Hz, Ar-H-6), 7.77 (d, 1H, 4J = 1.2 Hz, Ar-H-2), 7.98 (d, 1H, 3J = 8.4 Hz, Ar-H-5), 13.68 (s, 1H, 
COOH); 13C NMR (100 MHz, [D6]DMSO): δ = 56.75 (OCH3), 114.50, 121.27, 124.97, 135.67, 
141.88, 151.46, 165.76 (COOH); IR (ATR): ν = 3398, 2875, 2538, 1753, 1717, 1688, 1606, 1588, 
1524, 1494, 1455, 1411, 1356, 1300, 1254, 1230, 1184, 1122, 1088, 1013, 922, 880, 836, 745, 694, 
616 cm-1.  
General procedure G. Synthesis of Compounds 16a-f (with 16a as an Example). To a 
solution of compound 15a (2.32 g, 11.8 mmol) and TBTU (4.90 g, 15.3 mmol) in dichloromethane 
(80 mL) N-methylmorpholine (3.9 mL, 35.2 mmol) was added and the mixture was stirred at rt for 
15 min. Glycine methyl ester hydrochloride (2) (1.62 g, 12.9 mmol) was added and the mixture 
was stirred at rt for 2 h. The solvent was removed under reduced pressure, the residue was dissolved 
in ethyl acetate (20 mL) and the organic phase was washed with water (2 × 20 mL), saturated 
aqueous NaHCO3 solution (2 × 20 mL), 1 M HCl (2 × 20 mL) and brine (2 × 20 mL). The organic 
phase was dried over Na2SO4, filtered and the solvent removed under reduced pressure to afford 
16a (2.27 g) as a yellow solid. 
Methyl (3-methoxy-4-nitrobenzoyl)glycinate (16a). Yellow solid; yield 72% (2.27 g); mp: 
102-105 °C; 1H NMR (400 MHz, [D6]DMSO): δ = 3.68 (s, 3H, OCH3), 3.99 (s, 3H, OCH3), 4.07 
(d, 2H, 3J = 5.5  Hz, CH2), 7.59 (dd, 1H, 3J = 8.4 Hz, 4J = 1.6 Hz, Ar-H-6), 7.77 (d, 1H, 4J = 1.6 
Hz, Ar-H-2), 8.00 (d, 1H, 3J = 8.4 Hz, Ar-H-5), 9.28 (t, 1H, 3J = 5.5 Hz, NH); 13C NMR (100 MHz, 
[D6]DMSO): δ = 41.31 (CH2), 51.83 (COOCH3), 56.80 (OCH3), 113.01, 119.32, 125.04, 138.43, 
140.90, 151.62, 164.87 (CONH), 170.08 (COOCH3); IR (ATR): ν = 3346, 3075, 2965, 1738, 1643, 
1608, 1589, 1549, 1519, 1493, 1458, 1433, 1408, 1364, 1328, 1304, 1255, 1210, 1146, 1100, 1069, 
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1025, 1004, 966, 896, 837, 787, 772, 744, 705, 685, 639 cm-1; MS (ESI) m/z = 267.1 ([M-H]-); 
HRMS for C11H11N2O6: calculated 267.0617, found 267.0611. 
Methyl (4-amino-3-methoxybenzoyl)glycinate (17a). Synthesized according to General 
procedure A with methanol (20 mL) as solvent. Brown oil; yield 99% (1.845 g); 1H NMR (400 
MHz, [D6]DMSO): δ = 3.65 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.96 (d, 2H, 3J = 5.6 Hz, CH2), 
5.33 (s, 2H, NH2), 6.62 (d, 1H, 3J = 8.4 Hz, Ar-H-5), 7.30 (dd, 1H, 3J = 8.4 Hz, 4J = 1.2 Hz, Ar-H-
6), 7.33 (d, 1H, 4J = 1.2 Hz, Ar-H-2), 8.56 (t, 1H, 3J = 5.6 Hz, NH); 13C NMR (100 MHz, 
[D6]DMSO): δ = 41.63 (CH2), 52.09 (COOCH3), 55.77 (OCH3), 109.93, 112.51, 121.10, 121.71, 
141.78, 145.70, 167.05 (CONH), 171.31 (COOCH3); IR (ATR): ν = 3343, 2953, 1739, 1614, 1574, 
1543, 1503, 1463, 1438, 1406, 1367, 1301, 1207, 1181, 1146, 1075, 1032, 1012, 978, 873, 828, 
761 cm-1; MS (ESI) m/z = 239.1 (MH+); HRMS for C11H15N2O4: calculated 239.1032, found 
239.1038. 
General procedure H. Synthesis of Compounds 17c and 17f (with 17c as an Example). A 
mixture of compound 16c (143 mg, 0.42 mmol) and SnCl2 (394 mg, 2.08 mmol) in ethyl acetate (2 
mL) and ethanol (2 mL) was stirred at 55 °C for 24 h. The mixture was poured slowly into an 
aqueous NaHCO3 solution (20 mL) and stirred vigoroursly for 2 h, then extracted with EtOAc (20 
mL) and washed with brine (20 mL). The organic layer was dried over Na2SO4, filtered and the 
solvent was evaporated under reduced pressure. The residue was purified with flash column 
chromatography using dichloromethane/methanol (30/1 à 20/1) as an eluent to give compound 
17c (58 mg) as a brown oil. 
Methyl (4-amino-3-(benzyloxy)benzoyl)glycinate (17c). Brown oil; yield 44% (58 mg); 1H 
NMR (400 MHz, [D6]DMSO): δ = 3.65 (s, 3H, COOCH3), 3.96 (d, 2H, 3J = 5.6 Hz, NHCH2), 5.15 
(s, 2H, OCH2Ar), 5.37 (s, 2H, NH2), 6.66-7.53 (m, 8H, 8 × Ar-H), 8.55 (t, 1H, 3J = 5.6 Hz, NH); 
13C NMR (100 MHz, [D6]DMSO): δ = 41.14 (CH2COOCH3), 51.61 (COOCH3), 69.33 (OCH2Ar), 
111.07, 112.37, 120.62, 121.45, 127.38, 127.70, 128.37, 137.19, 141.59, 144.16, 166.46 (Ar-
CONH), 170.80 (COOCH3); IR (ATR): ν = 3344, 2951, 1742, 1614, 1574, 1543, 1503, 1454, 1435, 
1405, 1367, 1301, 1205, 1144, 1076, 1009, 925, 827, 759, 697 cm-1; MS (ESI) m/z = 315.1 (MH+); 
HRMS for C17H19N2O4: calculated 315.1345, found 315.1338. 
General procedure I. Synthesis of Compounds 18a-c (with 18a as an Example). To a 
suspension of 4,5-dibromopyrrole-2-carboxylic acid (296 mg, 1.10 mmol) and TBTU (405 mg, 
1.26 mmol) in dichloromethane (10 mL) N-methylmorpholine (350 µL, 3.15 mmol) was added and 
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the suspension was stirred at rt for 30 min upon which a clear solution formed. Compound 17a 
(145 mg, 1.05 mmol) and DMAP (14 mg, 0.115 mmol) were added and the mixture was stirred at 
60 °C for 15 h. The solvent was removed under reduced pressue, to the residue ethyl acetate (10 
ml) and water (10 mL) were added and the organic phase was washed with aqueous NaHCO3 
solution (10 mL), 1 M HCl (10 mL) and brine (2 × 10 mL), dried over Na2SO4, filtered and the 
solvent removed under reduced pressure. The crude product was purified with flash column 
chromatography using ethyl acetate/petroleum ether (1/1) as an eluent to obtain a white solid which 
was further purified by sonicating with ether (25 mL), filtering off the precipitate and drying to 
give 18a (40 mg) as a white solid. 
Methyl (4-(4,5-dibromo-1H-pyrrole-2-carboxamido)-3-methoxybenzoyl)glycinate (18a). 
White solid; yield 10% (40 mg); mp: 230-233 °C; 1H NMR (400 MHz, [D6]DMSO): δ = 3.67 (s, 
3H, OCH3), 3.92 (s, 3H, OCH3), 4.04 (d, 2H, 3J = 6.0 Hz, CONHCH2), 7.27 (d, 1H, 4J = 2.8 Hz, 
Pyrr-CH), 7.52 (dd, 1H, 3J = 8.4 Hz, 4J = 1.6 Hz, Ar-H-6), 7.57 (d, 1H, 4J = 1.6 Hz, Ar-H-2), 7.92 
(d, 1H, 3J = 8.4 Hz, Ar-H-5), 8.97 (t, 1H, 3J = 5.6 Hz, CONHCH2), 9.23 (s, 1H, CONH-Ar), 13.00 
(s, 1H, Pyrr-NH); 13C NMR (100 MHz, [D6]DMSO): δ = 41.24 (CH2), 51.74 (COOCH3), 55.89 
(OCH3), 98.40, 106.19, 110.07, 114.28, 119.63, 122.65, 127.53, 129.45, 130.03, 150.23, 157.12, 
166.00 (CONH), 170.45 (COOCH3); IR (ATR): ν = 3409, 3368, 3229, 3110, 2957, 1752, 1717, 
1650, 1600, 1547, 1523, 1487, 1433, 1411, 1391, 1374, 1350, 1310, 1270, 1251, 1214, 1178, 1134, 
1075, 1032, 1009, 973, 873, 806, 783, 755, 710, 652, 618 cm-1; MS (ESI) m/z = 485.9 ([M-H]-); 
HRMS for C16H14N3O5Br2: calculated 485.9300, found 485.9308; HPLC: Agilent Eclipse Plus C18 
column (5 µm, 4.6 × 150 mm); mobile phase: 30–90% of acetonitrile in TFA (0.1%) in 16 min, 
90% acetonitrile to 20 min; flow rate 1.0 mL/min; injection volume: 10 μL; retention time: 9.881 
min (99.0% at 280 nm). 
General procedure J. Synthesis of Compounds 19a-d and 19g (with 19a as an Example). To 
a stirred solution of compound 18a (34 mg, 0.070 mmol) in methanol (10 mL) 2 M NaOH (110 
µL, 0.210 mmol) was added. The mixture was stirred at rt for 15 h, concentrated under reduced 
pressure and the residue was acidified with 1 M HCl to pH 1. The product was extracted with ethyl 
acetate (2 × 10 mL), the combined organic phases washed with water (2 × 10 mL) and brine (10 
mL), dried over Na2SO4, filtered and the solvent evaporated under reduced pressure to afford 19a 
(18 mg) as a white solid. 
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(4-(4,5-Dibromo-1H-pyrrole-2-carboxamido)-3-methoxybenzoyl)glycine (19a). White solid; 
yield 94% (18 mg); mp: 272-275 °C; 1H NMR (400 MHz, [D6]DMSO): δ = 3.92-3.95 (m, 5H, CH2, 
CH3), 7.26 (d, 1H, 4J = 2.4 Hz, Pyrr-CH), 7.51-7.57 (m, 2H, Ar-H-2,5), 7.91 (d, 1H, 3J = 8.0 Hz, 
Ar-H-6), 8.84-8.87 (m, 1H, NHCH2), 9.23 (s, 1H, NHAr), 12.62 (s, 1H, COOH), 13.00 (s, 1H, 
Pyrr-NH); 13C NMR (100 MHz, [D6]DMSO): δ = 41.21 (CH2), 55.88 (OCH3), 98.40, 106.17, 
110.05, 114.26, 119.59, 122.65, 127.55, 129.33, 130.30, 150.22, 157.12, 165.88 (Ar-CONH), 
171.39 (COOH); IR (ATR): ν = 3401, 3209, 2841, 2528, 1719, 1702, 1663, 1620, 1665, 1594, 
1544, 1519, 1489, 1432, 1409, 1392, 1349, 1321, 1284, 1257, 1217, 1181, 1133, 1076, 1034, 1010, 
972, 897, 873, 802, 757, 684, 617 cm-1; MS (ESI) m/z = 471.9 ([M-H]-); HRMS for C15H12N3O5Br2: 
calculated 471.9144, found 471.9134; HPLC: Agilent Eclipse Plus C18 column (5 µm, 4.6 × 150 
mm); mobile phase: 30–90% of acetonitrile in TFA (0.1%) in 16 min, 90% acetonitrile to 20 min; 
flow rate 1.0 mL/min; injection volume: 10 μL; retention time: 8.191 min (95.9% at 280 nm). 
4,5-Dibromo-N-(4-((2-hydrazineyl-2-oxoethyl)carbamoyl)-2-isopropoxyphenyl)-1H-
pyrrole-2-carboxamide (20). Synthesized according to General procedure D with the addition of 
further 10 eq. of hydrazine monohydrate after 15 h (34 µL, 0.700 mmol) and stirring at reflux for 
additional 48 h. The product was isolated without evaporating the solvent but with filtering off the 
white precipitate (20, 34 mg) formed during reaction. White solid; yield 92% (34 mg); mp: 253-
257 °C; 1H NMR (400 MHz, [D6]DMSO): δ = 1.35 (d, 6H, 3J = 5.6 Hz, CH(CH3)2), 3.85 (d, 2H, 3J 
= 5.6 Hz, CH2), 4.29 (s, 2H, NH2), 4.71 (spt, 1H, 3J = 5.6 Hz, CH(CH3)2), 7.17 (s, 1H, Pyrr-CH), 
7.50-7.58 (m, 2H, Ar-H-2,6), 7.92 (d, 1H, 3J = 8.8 Hz, Ar-H-5), 8.72 (s, 1H, NHCH2), 9.04 (s, 1H, 
NHAr),  9.16 (s, 1H, CONHNH2), 13.02 (s, 1H, Pyrr-NH); 13C NMR (100 MHz, [D6]DMSO): δ = 
21.76 (CH(CH3)2), 41.39 (CH2), 71.31 (CH(CH3)2), 98.44, 106.31, 112.91, 113.81, 119.87, 122.47, 
127.61, 130.35, 130.41, 148.19, 157.02 (CONH), 165.86 (Ar-CONH), 168.38 (CONHNH2); IR 
(ATR): ν = 3419, 3316, 3204, 2969, 1660, 1619, 1599, 1510, 1483, 1441, 1418, 1389, 1354, 1302, 
1272, 1228, 1203, 1177, 1127, 968, 882, 809, 752, 695, 652, 613 cm-1; MS (ESI) m/z = 514.0 ([M-
H]-); HRMS for C17H18N5O4Br2: calculated 513.9726, found 513.9727; HPLC: Agilent Eclipse Plus 
C18 column (5 µm, 4.6 × 150 mm); mobile phase: 30–90% of acetonitrile in TFA (0.1%) in 16 
min, 90% acetonitrile to 20 min; flow rate 1.0 mL/min; injection volume: 10 μL; retention time: 
7.641 min (97.1% at 280 nm). 
4,5-Dibromo-N-(2-isopropoxy-4-(((5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-
yl)methyl)carbamoyl)phenyl)-1H-pyrrole-2-carboxamide (21). Synthesized according to 
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General procedure E and additionally purifying the crude product by adding ether (10 mL) to the 
crude product, sonicating the obtained suspension, filtering off the solid, washing with ether (2 × 
5 mL) and drying to give 21 (12 mg) as a white solid. Yield 39% (12 mg); mp: 160-162 °C; 1H 
NMR (400 MHz, [D6]DMSO): δ = 1.35 (d, 6H, 3J = 5.6 Hz, CH(CH3)2), 4.40 (d, 2H, 3J = 5.6 Hz, 
NHCH2), 4.70 (spt, 1H, 3J = 5.6 Hz, CH(CH3)2), 7.13 (s, 1H, Pyrr-CH), 7.50-7.57 (m, 2H, Ar-H-
2,6), 7.99 (d, 1H, Ar-H-5), 9.04 (t, 1H, 3J = 5.6 Hz,  NHCH2), 9.10 (s, 1H, NHAr), 12.35 (m, 2H, 
Pyrr-NH, NH); MS (ESI) m/z = 540.0 ([M-H]-); HRMS for C18H16Br2N5O5: calculated 539.9518, 
found 539.9518;  HPLC: Agilent Eclipse Plus C18 column (5 µm, 4.6 × 150 mm); mobile phase: 
30–90% of acetonitrile in TFA (0.1%) in 16 min, 90% acetonitrile to 20 min; flow rate 1.0 mL/min; 
injection volume: 10 μL; retention time: 10.671 min (95.1% at 280 nm). 
Methyl 4-aminobenzoate (23a). Synthesized according to General procedure F with heaing the 
reaction mixture at 70 °C. After the completion of the reaction, the solvent was evaporated under 
reduced pressure, the residue was dissolved in ethyl acetate (120 mL) and washed with aqueous 
NaHCO3 solution (3 × 40 mL) and brine (3 × 40 mL). The organic phase was dried over Na2SO4, 
filtered and the solvent removed under reduced pressure to obtain 23a (4.88g) as off-white crystals. 
Yield 89% (4.88 g); mp: 106-107 °C (107-110 °C, lit); 1H NMR (400 MHz, [D6]DMSO): δ = 3.88 
(s, 3H, CH3), 4.08 (s, 2H, NH2), 6.66 (d, 2H, 3J = 8.8 Hz, Ar-H-3,5), 7.87 (d, 2H, 3J = 8.8 Hz, Ar-
H-2,6); IR (ATR): ν = 3464, 3368, 3248, 2952, 1677, 1592, 1520, 1434, 1313, 1248, 1166, 1075, 
964, 835, 769, 698 cm-1. 
Methyl 4-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzoate (24a). To a suspension of 4,5-
dibromopyrrole-2-carboxylic acid (268 mg, 0.997 mmol) in anhydrous dichloromethane (9 mL) 
oxalyl chloride (392 µL, 4.48 mmol) was added and the mixture stirred at rt for 15 h. The solvent 
was removed under reduced pressure, fresh anhydrous dichloromethane (9 mL), pyridine (4.5 mL) 
and compound 23a (126 mg, 0.833 mmol) were added and the reaction mixture stirred at rt for 15 
h. The solvent was removed under reduced pressure, to the residue ethyl acetate (15 mL) and water 
(10 mL) were added. The undissolved solid was filtered off, phases were separated and the organic 
phase was washed with aqueous NaHCO3 solution (3 × 10 mL) and brine (2 × 10 mL), dried over 
Na2SO4, filtered and the solvent removed under reduced pressure. To the crude product methanol 
(10 mL) was added, the obtained suspension was sonicated, heated, filtered off, washed with 
methanol (2 × 5 mL) and dried to give 24a (96 mg) as a pale brown solid. Yield 29% (96 mg); mp: 
230-233 °C; 1H NMR (400 MHz, [D6]DMSO): δ = 3.84 (s, 3H, CH3), 7.30 (d, 1H, 4J = 2.4 Hz, 
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Pyrr-CH), 7.88 (d, 2H, 3J = 8.8 Hz, Ar-H-2,6), 7.96 (d, 2H, 3J = 8.8 Hz, Ar-H-3,5), 10.14 (s, 1H, 
CONH), 13.01 (d, 1H, 4J = 2.0 Hz, Pyrr-NH); 13C NMR (100 MHz, [D6]DMSO): δ = 51.89 (CH3), 
98.30, 106.68, 114.43, 119.10, 123.97, 127.50, 130.19, 143.36, 157.48, 165.80; IR (ATR): ν = 
3395, 3240, 3113, 2949, 1697, 1591, 1516, 1409, 1273, 1219, 1174, 1106, 974, 857, 816, 750 cm-
1; MS (ESI) m/z = 398.9 ([M-H]-); HRMS for C13H9Br2N2O3: calculated 398.8980, found 398.8985; 
HPLC: Agilent Eclipse Plus C18 column (4.6 mm × 150 mm); mobile phase: 30-90% acetonitrile 
in TFA (0.1%) in 16 min, 90% acetonitrile to 20 min; flow rate 1 mL/min; injection volume 10 µL; 
retention time: 11.022 (96.4 % at 280 nm). 
General procedure K. Synthesis of Compounds 25a-b and 29 (with 25a as an example). To 
a stirred solution of compound 24a (70 mg, 0.174 mmol) in a mixture of methanol and THF (3.5:1, 
9 mL) 1 M NaOH (696 µL, 0.696 mmol) was added. The mixture was stirred at rt for 15 h. 
Additional 4 eq. of 1 M NaOH (696 µL, 0.696 mmol) were added and the mixture was stirred at 
60 °C for 5 h, concentrated under reduced pressure, the basic water phase was washed with ethyl 
acetate (10 mL) and then acidified with 1 M HCl to pH 1. The product was extracted with ethyl 
acetate (3 × 15 mL), the combined organic phases washed with water (3 × 10 mL) and  brine (10 
mL), dried over Na2SO4, filtered and the solvent evaporated under reduced pressure. To the residue 
ether (15 mL) was added, the obtained suspension was sonicated, filtered, washed with ether (5 
mL) and dried to give 25a (42 mg) as a pale brown solid.  
4-(4,5-Dibromo-1H-pyrrole-2-carboxamido)benzoic acid (25a). Synthesized according to 
General procedure K. Pale brown solid; yield 62% (42mg); mp: >300 °C; 1H NMR (400 MHz, 
[D6]DMSO): δ = 7.29 (d, 1H, 4J = 2.8 Hz, Pyrr-CH), 7.84 (d, 2H, 3J = 8.8 Hz, Ar-H-3,5), 7.93 (d, 
2H, 3J = 8.8 Hz, Ar-H-2,6), 10.11 (s, 1H, CONH), 12.71 (br s, 1H, COOH), 13.00 (d, 1H, 4J = 2.4 
Hz, Pyrr-NH); 13C NMR (100 MHz, [D6]DMSO): δ =  98.28, 106.57, 114.35, 119.02, 125.19, 
127.55, 130.30, 142.97, 157.47, 166.91; IR (ATR): ν = 3206, 3121, 3071, 2965, 2845, 2656, 2551, 
1669, 1592, 1408, 1316, 1226, 1175, 1119, 975, 850, 768, 691 cm-1; MS (ESI) m/z = 384.9 ([M-
H]-); HRMS for C12H7Br2N2O3: calculated 384.8823, found 384.8827; HPLC: Agilent Eclipse Plus 
C18 column (4.6 mm × 150 mm); mobile phase: 30-90% acetonitrile in TFA (0.1%) in 16 min, 
90% acetonitrile to 20 min; flow rate 1 mL/min; injection volume 10 µL; retention time: 8.485 
(96.1 % at 280 nm). 
Methyl 2-hydroxy-4-(4-nitrobenzamido)benzoate (26). The solution of 4-nitrobenzoyl 
chloride (1) (0.550 g, 2.96 mmol) and methyl 4-amino-3-hydroxybenzoate (23b) (495 mg, 2.96 
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mmol) in anhydrous dichloromethane (20 mL) and pyridine (10 mL) was stirred at rt for 15 h. The 
solvent was removed under reduced pressure, the residue was dissolved in ethyl acetate (40 mL) 
and washed with water (2 × 15 mL), aqueous NaHCO3 solution (3 × 15 mL) and brine (2 × 10 mL). 
The organic phase was dried over Na2SO4, filtered and the solvent evaporated under reduced 
pressure. To the crude product ether (15 mL) was added, the obtained suspension sonicated, filtered 
off, washed with ether (2 × 5 mL) and dried to obtain 26 (641 mg) as a white solid. Yield 68% (641 
mg), mp: 200-202 °C; 1H NMR (400 MHz, [D6]DMSO): δ = 3.89 (s, 3H, CH3), 7.36 (dd, 1H, 3J = 
8.8 Hz, 4J = 2.0 Hz, Ar-H-5), 7.58 (d, 1H; 4J = 2.0 Hz, Ar-H-3), 7.81 (d, 1H, 3J = 8.8 Hz, Ar-H-6), 
8.18 (d, 2H, 3J = 9.2 Hz, Ar-H-2',6'), 8.38 (d, 2H, 3J = 9.2 Hz, Ar-H-3',5'), 10.65 (s, 1H, NH/OH), 
10.80 (s, 1H, OH/NH); 13C NMR (100 MHz, [D6]DMSO): δ = 52.27 (CH3), 107.36, 108.30, 111.43, 
123.56, 129.37, 130.72, 140.10, 145.10, 149.28, 160.93, 164.63, 168.88; IR (ATR): ν = 3380, 3112, 
2961, 1694, 1663, 1519, 1436, 1344, 1299, 1155, 1090, 954, 848, 710, 693, 631 cm-1; MS (ESI) 
m/z = 315.27 ([M-H]-). 
Methyl 4-(4-aminobenzamido)-2-hydroxybenzoate (27). Synthesized according to General 
procedure A. After evaporation of the solvent, ether (20 mL) was added to the residue, the obtained 
suspension sonicated, filtered, washed with ether (2 × 5 mL) and dried to afford 27 (458 mg) as 
white solid. Yield 83% (458 mg); mp: 207-210 °C; 1H NMR (400 MHz, [D6]DMSO): δ = 3.88 (s, 
3H, CH3), 5.87 (s, 2H, NH2), 6.61 (d, 2H, 3J = 8.8 Hz, Ar-H-3',5'), 7.34 (dd, 1H, 3J = 8.8 Hz, 4J = 
2.0 Hz, Ar-H-5), 7.58 (d, 1H, 4J = 2.0 Hz, Ar-H-3), 7.71-7.75 (m, 3H, Ar-H-2',6', Ar-H-6), 10.02 
(s, 1H, NH), 10.63 (s, 1H, OH); 13C NMR (100 MHz, [D6]DMSO): δ = 52.16 (CH3), 106.57, 
106.80, 111.17, 112.48, 120.32, 129.66, 130.36, 146.51, 152.59, 161.15, 165.71, 169.18; MS (ESI) 
m/z = 285.26 ([M-H]-); IR (ATR): ν = 3417, 3362, 3323, 3215 3101 2961, 2858, 1660, 1505, 1439, 
1348, 1238, 1195, 1148, 1076, 956, 834, 722, 660 cm-1. 
Methyl 4-(4-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzamido)-2-hydroxybenzoate 
(28). To a suspension of 4,5-dibromopyrrole-2-carboxylic acid (338 mg, 1.26 mmol) in anhydrous 
dichloromethane (10 mL) oxalyl chloride (2 M solution in dichloromethane, 3.8 mL, 7.55 mmol) 
was added and the mixture was stirred at rt for 15 h. The solvent was removed under reduced 
pressure, fresh anhydrous dichloromethane (10 mL), pyridine (5 mL) and compound 27 (290 mg, 
1.01 mmol) were added and the reaction mixture was stirred at rt for 15 h. The solvent was removed 
under reduced pressure, to the residue ethyl acetate (30 mL) and water (15 mL) were added. The 
undissolved solid was filtered off, phases were separated and the organic phase was washed with 
  32 
water (2 × 10 mL), aqueous NaHCO3 solution (3 × 10 mL) and brine (2 × 10 mL), dried over 
Na2SO4, filtered and the solvent was removed under reduced pressure. The solid residue after 
extraction was combined with the filtered solid and acetonitrile (20 mL) was added, the obtained 
suspension was sonicated, heated, filtered off, washed with acetonitrile (2 × 5 mL) and dried to 
give 28 (326 mg) as an off-white solid. Yield 60% (326 mg); mp: >300 °C; 1H NMR (400 MHz, 
[D6]DMSO): δ = 3.89 (s, 3H, CH3), 7.30 (d, 1H, 4J = 2.4 Hz, Pyrr-CH), 7.37 (dd, 1H, 3J = 8.8 Hz, 
4J = 2.0 Hz, Ar-H-5), 7.59 (d, 1H, 4J = 2.0 Hz, Ar-H-3), 7.78 (d, 1H, 3J = 8.8 Hz, Ar-H-6), 7.89 (d, 
2H, 3J = 8.8 Hz, Ar-H-2',6'), 7.98 (d, 2H, 3J = 8.8 Hz, Ar-H-3',5'), 10.13 (s, 1H, Pyrr-CONH-Ar), 
10.40 (s, 1H, Ar-CONH-Ar), 10.65 (s, 1H, OH), 13.01 (d, 1H, 4J = 2 Hz, Pyrr-NH); 13C NMR (100 
MHz, [D6]DMSO): δ =  52.23 (CH3), 98.29, 106.56, 106.97, 107.54, 111.31, 114.30, 118.98, 
127.58, 128.81, 130.56, 142.25, 145.85, 157.47, 161.06, 165.45, 169.05, two signals are 
overlapping; IR (ATR): ν = 3444, 3357, 3194, 2964, 1658, 1504, 1406, 1324, 1275, 1185, 1092, 
972, 826, 779, 684 cm-1; MS (ESI) m/z = 533.9 ([M-H]-); HRMS for C20H15Br2N3O5: calculated 
533.9300, found 533.9299; HPLC: Agilent Eclipse Plus C18 column (4.6 mm × 150 mm); mobile 
phase: 60-90% of methanol in 0.1% TFA in 16 min, 90% methanol to 20 min; flow rate 1 mL/min; 
injection volume 10 µL; retention time: 11.480 (95.9 % at 280 nm). 
4-(4-(4,5-Dibromo-1H-pyrrole-2-carboxamido)benzamido)-2-hydroxybenzoic acid (29). 
Synthesized according to General procedure K without washing the residue with ethyl acetate 
before acidifying it. To the crude product methanol (20 mL) was added, the obtained suspension 
was sonicated, filtered off, washed with methanol (2 × 10 mL) and ether (2 × 10 mL) and dried to 
give 29 (50 mg) as a pale yellow solid. Yield 64% (50 mg); mp: >300 °C; 1H NMR (400 MHz, 
[D6]DMSO): δ = 7.30 (d, 1H, 4J = 2.8 Hz, Pyrr-CH), 7.35 (dd, 1H, 3J = 8.8 Hz, 4J = 2.0 Hz, Ar-H-
5), 7.55 (d, 1H, 4J = 2.4 Hz, Ar-H-3), 7.76 (d, 1H, 3J = 8.4 Hz, Ar-H-6), 7.88 (d, 2H, 3J = 9.2 Hz, 
Ar-H-2',6'), 7.98 (d, 2H, 3J = 8.8 Hz, Ar-H-3',5'), 10.13 (s, 1H, Pyrr-CONH-Ar), 10.37 (s, 1H, Ar-
CONH-Ar), 11.38 (s, 1H, OH), 13.01 (d, 1H, 4J = 2.8 Hz, Pyrr-NH), 13.73 (br s, 1H, COOH); 13C 
NMR (100 MHz, [D6]DMSO):  δ = 98.30, 106.55, 106.77, 107.77, 111.06, 114.29, 118.98, 127.58, 
128.79, 128.87, 130.80, 142.21, 145.74, 157.46, 161.94, 165.43, 171.62; IR (ATR): ν = 3406, 3226, 
3110, 2547, 1644, 1498, 1334, 1229, 1111, 973, 892, 740, 671, 613 cm-1; MS (ESI) m/z = 519.9 
([M-H]-); HRMS for C19H13Br2N3O5: calculated 519.9144, found 519.9133; HPLC: Agilent Eclipse 
Plus C18 column (4.6 mm × 150 mm); mobile phase: 30-90% acetonitrile in 0.1% TFA in 16 min, 
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90% acetonitrile to 20 min; flow rate 1 mL/min; injection volume 10 µL; retention time: 10.212 
(96.5 % at 280 nm). 
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New N-phenylpyrrolamides were prepared as DNA gyrase and topoisomerase IV inhibitors and their structure-activity 
relationships were studied. Most potent compounds displayed IC50 values lower than 100 nM against E. coli gyrase. Minimum 
inhibitory concentration of 12.5 µM was determined for 11 against Gram-positive E. faecalis. MICs against efflux pump deficient 
and against the E. coli strains in the presence of efflux pump inhibitor were studied. 
 
